In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.
In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment of metastatic disease can be applied in the neo adjuvant setting for colorectal cancer by discussing data from the FOXTROT and NICHE trials and the adjuvant setting for gastric cancer by discussing data from CheckMate 577. Finally, the experts consider new promising data on targeting KRAS compared to the MEK and the ERK inhibitors.
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic...
This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and...
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins...